Denner isnt the only one. Proven guys like Hugh Cole wouldnt leave a seemingly great position at Shire to come to a company with no future.
To me Iclusig in CML is a lost opportunity and should be discounted entirely as a viable revenue stream. No sense in beating a dead horse. Iclusig in other indications and 113 will take time to play out. Not everyone can afford to wait 2 years but I would bet my last dollar that both drugs will find their way.